The role of human cytochrome P450 enzymes in metabolism of acrylamide in vitro

被引:13
作者
Kraus, Daria [1 ]
Rokitta, Dennis [1 ]
Fuhr, Uwe [1 ]
Tomalik-Scharte, Dorota [1 ]
机构
[1] Univ Cologne, Dept Pharmacol, D-50931 Cologne, Germany
关键词
Acrylamide metabolism; glycidamide; human CYP2E1 metabolism; DIETARY ACRYLAMIDE; MERCAPTURIC ACIDS; DIALLYL SULFIDE; RISK-ASSESSMENT; HUMAN URINE; GLYCIDAMIDE; CANCER; 2E1; DNA; INHIBITION;
D O I
10.3109/15376516.2012.759307
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Objective: Acrylamide (AA), a probable human carcinogen, is present in fried and baked starch-rich food. In vivo, the substance is partly biotransformed to glycidamide (GA), which may account for carcinogenic effects. Existing data suggest an important but not exclusive contribution of CYP2E1 to GA formation. The aim of this project was to derive respective enzyme kinetic parameters for CYP2E1 and to assess a possible role of other important human CYPs for this reaction in vitro. Methods: AA (0.2-20 mM) was incubated with human liver microsomes (HLM) and human cytochrome P450 enzymes (supersomes (TM)). GA was quantified by a specific LC-MS/MS method. Enzyme kinetic parameters were estimated assuming a single binding site. Furthermore, inhibition experiments were performed with diethyldithiocarbamate (DDC), a potent inhibitor of CYP2E1. Results: The mean +/- SD maximum formation rate (V-max) and Michaelis-Menten constant (K-m) for GA formation in HLM were 199 +/- 36 pmol GA/mg protein/min and 3.3 +/- 0.5 mM, respectively. In AA incubations with supersomes (TM), only for CYP2E1 measurable GA formation was detected in all tested AA concentrations (V-max and K-m were 5.4 nmol GA/nmol CYP2E1/min and 1.3 mM, respectively). Inhibition constant (IC50) of DDC was 3.1 +/- 0.5 mu M for HLM and 1.2 +/- 0.2 mu M for CYP2E1 supersomes (TM). Therefore, relevant participation of CYPs other than CYP2E1 in the metabolism of AA to GA in humans does not seem likely. Conclusion: Our results confirm the major role of CYP2E1 in GA formation from AA, albeit with low affinity and low capacity. Further studies are needed to identify other pathways of GA formation.
引用
收藏
页码:346 / 351
页数:6
相关论文
共 50 条
  • [31] Effects of catalpol on the activity of human liver cytochrome P450 enzymes
    Liu, Lu
    Cao, Xiangang
    Li, Tingxin
    Li, Xiaohua
    XENOBIOTICA, 2019, 49 (11) : 1289 - 1295
  • [32] Inhibitory effects of cornuside on human liver cytochrome P450 enzymes
    Yang, Yanmo
    Zhang, Ke
    Zhou, Mi
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2025,
  • [33] In vitro inhibition and induction of human cytochrome P450 enzymes by SIPI5357, a potential antidepressant
    Fan, Gaoning
    Cao, Yun
    Yang, Jin
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2015, 36 (06) : 364 - 372
  • [34] Highly miniaturized formats for in vitro drug metabolism assays using Vivid® fluorescent substrates and recombinant human cytochrome P450 enzymes
    Trubetskoy, OV
    Gibson, JR
    Marks, BD
    JOURNAL OF BIOMOLECULAR SCREENING, 2005, 10 (01) : 56 - 66
  • [35] Metabolism of bilirubin by human cytochrome P450 2A6
    Abu-Bakar, A'edah
    Arthur, Dionne M.
    Wikman, Anna S.
    Rahnasto, Minna
    Juvonen, Risto O.
    Vepsalainen, Jouko
    Raunio, Hannu
    Ng, Jack C.
    Lang, Matti A.
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2012, 261 (01) : 50 - 58
  • [36] In Vitro Cytochrome P450 Inhibition and Induction
    Walsky, Robert L.
    Boldt, Sherri E.
    CURRENT DRUG METABOLISM, 2008, 9 (09) : 928 - 939
  • [37] Cancer treatment and pharmacogenetics of cytochrome P450 enzymes
    van Schaik, RHN
    INVESTIGATIONAL NEW DRUGS, 2005, 23 (06) : 513 - 522
  • [38] Inhibition of Cytochrome P450 Enzymes by Quinones and Anthraquinones
    Sridhar, Jayalakshmi
    Liu, Jiawang
    Foroozesh, Maryam
    Stevens, Cheryl L. Klein
    CHEMICAL RESEARCH IN TOXICOLOGY, 2012, 25 (02) : 357 - 365
  • [39] Effects of icaritin on cytochrome P450 enzymes in rats
    Liang, Dong-Lou
    Zheng, Shuang-li
    PHARMAZIE, 2014, 69 (04): : 301 - 305
  • [40] Cancer treatment and pharmacogenetics of cytochrome P450 enzymes
    Ron H. N. van Schaik
    Investigational New Drugs, 2005, 23 : 513 - 522